rs2294597

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_015192.4(PLCB1):​c.3337C>T​(p.Leu1113Leu) variant causes a splice region, synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.295 in 1,600,448 control chromosomes in the GnomAD database, including 72,118 homozygotes. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Benign (★★). Synonymous variant affecting the same amino acid position (i.e. L1113L) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.25 ( 5335 hom., cov: 33)
Exomes 𝑓: 0.30 ( 66783 hom. )

Consequence

PLCB1
NM_015192.4 splice_region, synonymous

Scores

2
Splicing: ADA: 0.0007654
2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:12

Conservation

PhyloP100: 1.43

Publications

18 publications found
Variant links:
Genes affected
PLCB1 (HGNC:15917): (phospholipase C beta 1) The protein encoded by this gene catalyzes the formation of inositol 1,4,5-trisphosphate and diacylglycerol from phosphatidylinositol 4,5-bisphosphate. This reaction uses calcium as a cofactor and plays an important role in the intracellular transduction of many extracellular signals. This gene is activated by two G-protein alpha subunits, alpha-q and alpha-11. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
PLCB1 Gene-Disease associations (from GenCC):
  • genetic developmental and epileptic encephalopathy
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
  • developmental and epileptic encephalopathy, 12
    Inheritance: AR Classification: STRONG, MODERATE Submitted by: Labcorp Genetics (formerly Invitae), G2P, Ambry Genetics
  • infantile spasms
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • malignant migrating partial seizures of infancy
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.49).
BP6
Variant 20-8790175-C-T is Benign according to our data. Variant chr20-8790175-C-T is described in ClinVar as Benign. ClinVar VariationId is 129914.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=1.43 with no splicing effect.
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.338 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
PLCB1NM_015192.4 linkc.3337C>T p.Leu1113Leu splice_region_variant, synonymous_variant Exon 31 of 32 ENST00000338037.11 NP_056007.1 Q9NQ66-1
PLCB1NM_182734.3 linkc.3337C>T p.Leu1113Leu splice_region_variant, synonymous_variant Exon 31 of 33 NP_877398.1 Q9NQ66-2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
PLCB1ENST00000338037.11 linkc.3337C>T p.Leu1113Leu splice_region_variant, synonymous_variant Exon 31 of 32 1 NM_015192.4 ENSP00000338185.6 Q9NQ66-1

Frequencies

GnomAD3 genomes
AF:
0.252
AC:
38220
AN:
151918
Hom.:
5336
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.142
Gnomad AMI
AF:
0.231
Gnomad AMR
AF:
0.218
Gnomad ASJ
AF:
0.279
Gnomad EAS
AF:
0.156
Gnomad SAS
AF:
0.352
Gnomad FIN
AF:
0.300
Gnomad MID
AF:
0.212
Gnomad NFE
AF:
0.318
Gnomad OTH
AF:
0.233
GnomAD2 exomes
AF:
0.274
AC:
67376
AN:
245544
AF XY:
0.283
show subpopulations
Gnomad AFR exome
AF:
0.142
Gnomad AMR exome
AF:
0.196
Gnomad ASJ exome
AF:
0.304
Gnomad EAS exome
AF:
0.158
Gnomad FIN exome
AF:
0.287
Gnomad NFE exome
AF:
0.312
Gnomad OTH exome
AF:
0.280
GnomAD4 exome
AF:
0.299
AC:
433600
AN:
1448412
Hom.:
66783
Cov.:
28
AF XY:
0.302
AC XY:
217815
AN XY:
720770
show subpopulations
African (AFR)
AF:
0.138
AC:
4579
AN:
33098
American (AMR)
AF:
0.198
AC:
8800
AN:
44476
Ashkenazi Jewish (ASJ)
AF:
0.304
AC:
7895
AN:
26002
East Asian (EAS)
AF:
0.157
AC:
6183
AN:
39378
South Asian (SAS)
AF:
0.341
AC:
29139
AN:
85398
European-Finnish (FIN)
AF:
0.288
AC:
15337
AN:
53164
Middle Eastern (MID)
AF:
0.224
AC:
1290
AN:
5754
European-Non Finnish (NFE)
AF:
0.312
AC:
343238
AN:
1101310
Other (OTH)
AF:
0.286
AC:
17139
AN:
59832
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.469
Heterozygous variant carriers
0
12695
25390
38085
50780
63475
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
10978
21956
32934
43912
54890
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.251
AC:
38228
AN:
152036
Hom.:
5335
Cov.:
33
AF XY:
0.251
AC XY:
18642
AN XY:
74290
show subpopulations
African (AFR)
AF:
0.142
AC:
5902
AN:
41486
American (AMR)
AF:
0.217
AC:
3324
AN:
15284
Ashkenazi Jewish (ASJ)
AF:
0.279
AC:
968
AN:
3468
East Asian (EAS)
AF:
0.156
AC:
805
AN:
5170
South Asian (SAS)
AF:
0.352
AC:
1696
AN:
4818
European-Finnish (FIN)
AF:
0.300
AC:
3164
AN:
10546
Middle Eastern (MID)
AF:
0.184
AC:
54
AN:
294
European-Non Finnish (NFE)
AF:
0.318
AC:
21612
AN:
67954
Other (OTH)
AF:
0.234
AC:
493
AN:
2108
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.501
Heterozygous variant carriers
0
1457
2913
4370
5826
7283
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
406
812
1218
1624
2030
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.293
Hom.:
17581
Bravo
AF:
0.238
Asia WGS
AF:
0.259
AC:
903
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:12
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Developmental and epileptic encephalopathy, 12 Benign:4
-
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Oct 10, 2014
Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Sep 05, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:3
Apr 25, 2013
Genetic Services Laboratory, University of Chicago
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jul 15, 2024
Unidad de Genómica Garrahan, Hospital de Pediatría Garrahan
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is classified as Benign based on local population frequency. This variant was detected in 38% of patients studied in a panel designed for Epileptic and Developmental Encephalopathy and Progressive Myoclonus Epilepsy. Number of patients: 35. Only high quality variants are reported. -

-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:3
Nov 24, 2020
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Apr 20, 2017
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Early Infantile Epileptic Encephalopathy, Autosomal Recessive Benign:1
Jun 14, 2016
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Inborn genetic diseases Benign:1
Jan 08, 2016
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.49
CADD
Benign
12
DANN
Benign
0.85
PhyloP100
1.4
PromoterAI
-0.022
Neutral
Mutation Taster
=71/29
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Benign
0.00077
dbscSNV1_RF
Benign
0.19
Splicevardb
2.0
SpliceAI score (max)
0.040
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs2294597; hg19: chr20-8770822; COSMIC: COSV62057501; COSMIC: COSV62057501; API